MA53400A - Hétéromultimères alk7: actriib et leurs utilisations - Google Patents

Hétéromultimères alk7: actriib et leurs utilisations

Info

Publication number: MA53400A
Authority: MA; Morocco
Prior art keywords: actriib; alk7 heteromultimers; alk7; heteromultimers
Prior art date: 2015-04-06

Application number

MA053400A

Other languages

English (en)

Inventor

Roselyne Castonguay

Yossi Dagon

Asya Grinberg

John Knopf

Ravindra Kumar

Gang Li

Robert Scott Pearsall

Dianne S Sako

Original Assignee

Acceleron Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-06

Filing date

2016-04-06

Publication date

2021-08-04

2016-04-06 Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc

2021-08-04 Publication of MA53400A publication Critical patent/MA53400A/fr

Links

102100034135 Activin receptor type-1C Human genes 0.000 title 1
101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 title 1
101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Epidemiology (AREA)

MA053400A 2015-04-06 2016-04-06 Hétéromultimères alk7: actriib et leurs utilisations MA53400A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201562143579P	2015-04-06	2015-04-06

Publications (1)

Publication Number	Publication Date
MA53400A true MA53400A (fr)	2021-08-04

Family

ID=57072866

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
MA041916A MA41916A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41920A MA41920B1 (fr)	2015-04-06	2016-04-06	Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA054328A MA54328A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA053400A MA53400A (fr)	2015-04-06	2016-04-06	Hétéromultimères alk7: actriib et leurs utilisations

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
MA041916A MA41916A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations
MA41920A MA41920B1 (fr)	2015-04-06	2016-04-06	Protéines de fusion de récepteur type i et type ii à bras unique et leurs utilisations
MA054328A MA54328A (fr)	2015-04-06	2016-04-06	Hétéromultimères de récepteur de type i et de type ii de la superfamille de tgf-bêta et leurs utilisations

Country Status (15)

Country	Link
US (7)	US10227392B2 (fr)
EP (5)	EP3280728B1 (fr)
JP (3)	JP7055636B2 (fr)
KR (2)	KR20180002661A (fr)
CN (4)	CN115073610A (fr)
AU (4)	AU2016244750B2 (fr)
BR (1)	BR112017021510A2 (fr)
CA (2)	CA2981833A1 (fr)
DK (1)	DK3280728T3 (fr)
EA (2)	EA037293B1 (fr)
ES (2)	ES3057446T3 (fr)
HK (2)	HK1250373A1 (fr)
MA (4)	MA41916A (fr)
MX (1)	MX391964B (fr)
WO (2)	WO2016164503A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2014308751B2 (en)	2013-08-22	2020-03-05	Acceleron Pharma, Inc.	TGF-beta receptor type II variants and uses thereof
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
BR112017021510A2 (pt)	2015-04-06	2018-07-03	Acceleron Pharma Inc	heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
KR20170141215A (ko)	2015-04-06	2017-12-22	악셀레론 파마 인코포레이티드	싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
SI3286206T1 (sl)	2015-04-22	2021-07-30	Biogen Ma Inc.	Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
CN116327952A (zh)	2015-08-04	2023-06-27	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
CN105254764A (zh) *	2015-08-27	2016-01-20	上海康岱生物医药技术有限公司	ACVR1-Fc融合蛋白及其制法和用途
EP3439741B1 (fr)	2016-04-06	2026-05-20	Acceleron Pharma Inc	Hétéromultimères actriib:alk7 pour la réduction thérapeutique du poids corporel
CN116531490A (zh)	2016-07-15	2023-08-04	阿塞勒隆制药公司	用于治疗肺高血压的组合物和方法
WO2018067879A1 (fr)	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Hétéromultimères alk4:actriib et leurs utilisations
CA3039074A1 (fr) *	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Compositions et methode pour le traitement de la renopathie
KR102761094B1 (ko)	2016-10-05	2025-02-03	악셀레론 파마 인코포레이티드	변이체 actriib 단백질 및 이의 용도
JP7097354B2 (ja) *	2016-10-05	2022-07-07	アクセルロンファーマインコーポレイテッド	Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN119241685A (zh)	2016-11-10	2025-01-03	科乐斯疗法公司	激活素受体iia型变体及其使用方法
DK3541833T5 (da) *	2016-11-17	2024-09-02	2Seventy Bio Inc	TGFß signalkonverter
KR20190115037A (ko) *	2017-02-01	2019-10-10	악셀레론 파마 인코포레이티드	면역 활성을 증가시키는데 이용되는 TGFβ 및 ActRII
BR112019023071A2 (pt)	2017-05-04	2020-06-09	Acceleron Pharma Inc	proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
EP3424957A1 (fr) *	2017-07-03	2019-01-09	advanceCOR GmbH	Protéine de fusion
JP7433224B2 (ja) *	2017-11-02	2024-02-19	バイエル・アクチエンゲゼルシヤフト	Ａｌｋ－１およびｂｍｐｒ－２に結合する二重特異性抗体
KR20200109330A (ko)	2018-01-12	2020-09-22	케로스 테라퓨틱스, 인크.	액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
AU2019216761B2 (en)	2018-02-09	2025-04-10	Acceleron Pharma Inc.	Methods for treating heterotopic ossification
WO2019173324A1 (fr)	2018-03-06	2019-09-12	The Trustees Of The University Of Pennsylvania	Récepteurs d'antigène chimérique spécifique à l'antigène prostatique spécifique membranaire et leurs procédés d'utilisation
WO2019213446A1 (fr)	2018-05-03	2019-11-07	Acceleron Pharma Inc.	NOUVEAUX LIANTS DE LIGANDS DE LA SUPERFAMILLE DES TGFβ ET LEURS UTILISATIONS
WO2019213442A1 (fr)	2018-05-03	2019-11-07	Acceleron Pharma Inc.	LIANTS MULTISPÉCIFIQUES DE LIGANDS DE LA SUPERFAMILLE DE TGFβ ET LEURS UTILISATIONS
WO2019217715A1 (fr)	2018-05-09	2019-11-14	Keros Therapeutics, Inc.	Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation
WO2019226617A1 (fr)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk
WO2019226658A1 (fr)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation
WO2019241625A1 (fr) *	2018-06-15	2019-12-19	Acceleron Pharma Inc.	Protéines de fusion bi- et tri-fonctionnelles et utilisations associées
MX2021013588A (es)	2019-05-08	2022-02-11	Medigene Immunotherapies Gmbh	Células t genomodificadas.
US20220362333A1 (en) *	2019-07-26	2022-11-17	Board Of Trustees Of Michigan State University	Methods Of Preventing Or Treating Fatty Degeneration Of Skeletal Muscle
CN112625137B (zh) *	2019-10-08	2021-10-08	北京东方百泰生物科技股份有限公司	一种人白细胞介素10-Fc融合蛋白及其医药用途
MX2022009553A (es) *	2020-02-03	2022-11-07	Acceleron Pharma Inc	Proteínas actriib variantes y sus usos.
CN115515618A (zh) *	2020-03-13	2022-12-23	阿塞勒隆制药公司	用于治疗肾脏疾病或病症的单臂ActRIIA和ActRIIB异多聚体和方法
EP4121088A4 (fr)	2020-03-20	2024-07-03	Keros Therapeutics, Inc.	Procédés d'utilisation de variants de récepteur de l'activine de type iib
CA3176735A1 (fr)	2020-03-20	2021-09-23	Keros Therapeutics, Inc.	Chimeres de type ii du recepteur d'activine et leurs methodes d'utilisation
EP4142769A4 (fr)	2020-04-28	2024-05-15	Acceleron Pharma Inc.	Protéines actrii et leur utilisation dans le traitement de l'hypertension pulmonaire post-capillaire
KR102587871B1 (ko) *	2020-06-19	2023-10-12	숙명여자대학교산학협력단	Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체 및 이의 용도
KR20230117348A (ko) *	2020-11-04	2023-08-08	에이치큐 한	Tgf-베타 계열의 다중 리간드를 저해할 수 있는 신규한 이작용성 다중특이적 길항제 및 이의 용도
CA3211507A1 (fr) *	2021-03-10	2022-09-15	Rajasekhar Naga Venkata Sai Suragani	Antagonistes de l'actrii-alk4 et methodes de traitement de l'insuffisance cardiaque
WO2022192404A1 (fr) *	2021-03-10	2022-09-15	Acceleron Pharma Inc.	Antagonistes de l'actrii-alk4 et méthodes de traitement de l'insuffisance cardiaque
WO2024182505A1 (fr) *	2023-03-01	2024-09-06	The Regents Of The University Of California	Utilisation d'inhibiteurs alk1 du récepteur bmp dans des thérapies contre l'arthrose
WO2025034616A1 (fr) *	2023-08-04	2025-02-13	Lask Pharma, Inc.	Protéines de type 1b du récepteur de protéine morphogénétique osseuse soluble (bmp) et leurs utilisations
WO2025137390A1 (fr) *	2023-12-20	2025-06-26	Arrowhead Pharmaceuticals, Inc.	Agents arni pour l'inhibition de l'expression de la kinase 7 de type récepteur de l'activine (alk7), leurs compositions et leurs procédés d'utilisation

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5955A (en)		1848-12-05		Plate for boiler-holes in cooking-stoves
EP0105014B1 (fr)	1982-09-24	1992-05-20	THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce	Rétablissement de tissu chez les animaux
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
ES2052027T5 (es)	1988-11-11	2005-04-16	Medical Research Council	Clonacion de secuencias de dominio variable de inmunoglobulina.
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5567588A (en)	1990-06-11	1996-10-22	University Research Corporation	Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5580737A (en)	1990-06-11	1996-12-03	Nexstar Pharmaceuticals, Inc.	High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
KR970002255B1 (ko)	1990-06-11	1997-02-26	넥스스타 파아마슈티컬드, 인크.	핵산 리간드
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5707796A (en)	1990-06-11	1998-01-13	Nexstar Pharmaceuticals, Inc.	Method for selecting nucleic acids on the basis of structure
US5763177A (en)	1990-06-11	1998-06-09	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
ES2113940T3 (es)	1990-12-03	1998-05-16	Genentech Inc	Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US20050186593A1 (en) *	1991-05-10	2005-08-25	The Salk Institute For Biological Studies	Cloning and recombinant production of CRF receptor(s)
ATE255131T1 (de)	1991-06-14	2003-12-15	Genentech Inc	Humanisierter heregulin antikörper
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (fr)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions induisant la destruction de cellules infectees par l'hiv
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
WO1993016185A2 (fr)	1992-02-06	1993-08-19	Creative Biomolecules, Inc.	Proteine de liaison biosynthetique pour marqueur de cancer
WO1994011502A2 (fr)	1992-11-17	1994-05-26	Ludwig Institute For Cancer Research	Kinases du type recepteurs activine, proteines possedant des domaines de kinase de serine/threonine et leur utilisation
US7592428B1 (en)	1992-11-17	2009-09-22	Ludwig Institute For Cancer Research	Antibodies which bind specifically to activin receptor like kinases
US5677196A (en)	1993-05-18	1997-10-14	University Of Utah Research Foundation	Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en)	1994-03-29	1996-06-11	Onyx Pharmaceuticals, Inc.	Reverse two-hybrid method
US5614609A (en)	1994-10-20	1997-03-25	Carlos F. Ibanez	Serine threonine kinase receptor
US5814565A (en)	1995-02-23	1998-09-29	University Of Utah Research Foundation	Integrated optic waveguide immunosensor
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
NZ502795A (en)	1995-04-11	2001-09-28	Gen Hospital Corp	Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6699843B2 (en)	1995-06-07	2004-03-02	Gilead Sciences, Inc.	Method for treatment of tumors using nucleic acid ligands to PDGF
JPH10303327A (ja)	1997-04-23	1998-11-13	Yamaichi Electron Co Ltd	半導体チップの接点変換構造と該接点変換構造を有する半導体チップの製造法
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US6011577A (en)	1997-06-30	2000-01-04	Polaroid Corporation	Modular optical print head assembly
JP2001513982A (ja)	1997-08-29	2001-09-11	ヒューマンジノームサイエンシーズ，インコーポレイテッド	フォリスタチン−３
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
ES2375931T3 (es)	1997-12-05	2012-03-07	The Scripps Research Institute	Humanización de anticuerpo murino.
US6335155B1 (en)	1998-06-26	2002-01-01	Sunesis Pharmaceuticals, Inc.	Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
JP2002533726A (ja)	1998-12-28	2002-10-08	サネシスファーマシューティカルスインコーポレイテッド	結合のための小有機分子リガンドの同定
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
NZ513642A (en)	1999-01-21	2004-02-27	Metamorphix Inc	Growth differentiation factor inhibitors and uses therefor
DE60042021D1 (de)	1999-07-29	2009-05-28	Gilead Sciences Inc	Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
EP1240319A1 (fr)	1999-12-15	2002-09-18	Genentech, Inc.	Balayage aveugle, procede combinatoire permettant la representation d'epitopes de proteines fonctionnelles
AU2001247616B2 (en)	2000-04-11	2007-06-14	Genentech, Inc.	Multivalent antibodies and uses therefor
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
IL155977A0 (en)	2000-11-30	2003-12-23	Medarex Inc	Transgenic transchromosomal rodents for making human antibodies
CA2488441C (fr)	2002-06-03	2015-01-27	Genentech, Inc.	Bibliotheques de phages et anticorps synthetiques
US20040223966A1 (en)	2002-10-25	2004-11-11	Wolfman Neil M.	ActRIIB fusion polypeptides and uses therefor
US20050079574A1 (en)	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
EP2135952A3 (fr)	2003-09-15	2010-09-29	Research Development Foundation	Crypto-antagonisme d'activine et signalisation béta TGF
US20070135336A1 (en)	2003-09-15	2007-06-14	De Kretser David	Follistatin isoforms and uses thereof
US7456149B2 (en)	2004-03-02	2008-11-25	Acceleron Pharma, Inc.	ALK7 and myostatin inhibitors and uses thereof
CA2561686C (fr)	2004-03-31	2014-12-02	Genentech, Inc.	Anticorps anti-tgf-beta humanises
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
PT1737891E (pt)	2004-04-13	2013-04-16	Hoffmann La Roche	Anticorpos anti p-selectina
EP3489257A1 (fr)	2004-07-23	2019-05-29	Acceleron Pharma Inc.	Polypeptides du récepteur actrii, procédés et compositions
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
ES2579805T3 (es)	2004-09-23	2016-08-16	Genentech, Inc.	Anticuerpos y conjugados modificados por ingeniería genética con cisteína
EP1957531B1 (fr)	2005-11-07	2016-04-13	Genentech, Inc.	Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl
EP2781222B1 (fr)	2005-11-23	2017-08-02	Acceleron Pharma, Inc.	Antagonistes de l'activine-actriia destinés à être utilisés pour la promotion de la croissance osseuse
CN101370511B (zh) *	2005-11-23	2015-07-01	阿塞勒隆制药公司	Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
WO2007064919A2 (fr)	2005-12-02	2007-06-07	Genentech, Inc.	Polypeptides de liaison avec des sequences de diversite limitees
CA2651567A1 (fr)	2006-05-09	2007-11-22	Genentech, Inc.	Polypeptides de liaison a squelettes optimises
MX2008015263A (es) *	2006-06-02	2008-12-17	Wyeth Corp	Uso de proteinas y pepetidos de la superfamilia del factor beta transformador de crecimiento para purificacion y metodos terapeuticos.
WO2007147901A1 (fr)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production d'anticorps bispécifiques
WO2008030367A2 (fr)	2006-09-01	2008-03-13	The General Hospital Corporation	Inhibiteurs sélectifs de la myostatine
CN111518218A (zh) *	2006-11-02	2020-08-11	阿塞勒隆制药公司	Alk1受体和配体拮抗剂及其用途
CA2671983A1 (fr)	2006-12-08	2009-06-19	Acceleron Pharma Inc.	Utilisations de cerberus, de coco et de leurs derives
WO2008076437A2 (fr) *	2006-12-18	2008-06-26	Acceleron Pharma Inc.	Antagonistes de l'activine-actrii et ses utilisations pour accroître les niveaux de globules rouges
TW201803890A (zh)	2007-02-02	2018-02-01	艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
US7947646B2 (en)	2007-03-06	2011-05-24	Amgen Inc.	Variant activin receptor polypeptides
EP2574671B1 (fr)	2007-03-19	2016-02-03	National Research Council Of Canada	Antagonistes de ligands et leurs utilisations
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
EP3663318A1 (fr)	2008-01-07	2020-06-10	Amgen Inc.	Procédé de fabrication de molécules hétérodimères fc d'anticorps utilisant les effets de conduite électrostatique
WO2010031168A1 (fr)	2008-09-17	2010-03-25	National Research Council Of Canada	Agents de liaison hétéro-multivalents pour des membres de la superfamille des tgf-β
KR20190128254A (ko) *	2008-05-02	2019-11-15	악셀레론 파마 인코포레이티드	혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
TWI626945B (zh)	2008-08-14	2018-06-21	艾瑟勒朗法瑪公司	使用ｇｄｆ阱以增加紅血球水平
NZ627111A (en) *	2008-11-26	2015-10-30	Amgen Inc	Variants of activin iib receptor polypeptides and uses thereof
AU2010204985A1 (en)	2009-01-13	2011-08-04	Acceleron Pharma Inc.	Methods for increasing adiponectin
EP3058986B1 (fr) *	2009-03-30	2018-05-09	Acceleron Pharma Inc.	Antagonistes de bmp-alk3 et utilisations pour favoriser la croissance osseuse
EP3290439B1 (fr)	2009-06-12	2020-09-02	Acceleron Pharma Inc.	Protéines de fusion actriib-fc tronquées
MX2012003396A (es)	2009-09-16	2012-04-10	Genentech Inc	Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
FR2951408B1 (fr)	2009-10-15	2012-01-13	Renault Sa	Cadre moteur pour moteur electrique de vehicule automobile
AR080794A1 (es) *	2010-03-26	2012-05-09	Hoffmann La Roche	Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
WO2012027065A2 (fr) *	2010-08-27	2012-03-01	Celgene Corporation	Polythérapie pour traiter des maladies
CN102850458B (zh)	2011-06-28	2014-10-01	华博生物医药技术（上海）有限公司	新型重组双功能融合蛋白及其制法和用途
WO2013063536A1 (fr)	2011-10-27	2013-05-02	Acceleron Pharma, Inc.	AGENTS DE LIAISON À ActRIIB ET UTILISATIONS DE CEUX-CI
DK2831105T3 (da)	2012-03-28	2017-11-20	Univ Texas	Tgf-type ii-type iii-receptorfusioner
AU2014308751B2 (en)	2013-08-22	2020-03-05	Acceleron Pharma, Inc.	TGF-beta receptor type II variants and uses thereof
WO2016090035A2 (fr)	2014-12-02	2016-06-09	La Jolla Institute For Allergy And Immunology	Modulateurs de l'activine et procédés de modulation de réponses immunitaires et de cellules t auxiliaires folliculaires
BR112017021510A2 (pt)	2015-04-06	2018-07-03	Acceleron Pharma Inc	heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
KR20170141215A (ko)	2015-04-06	2017-12-22	악셀레론 파마 인코포레이티드	싱글-암 유형 i과 유형 ii 수용체 융합 단백질들 및 이들의 용도
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
SI3286206T1 (sl)	2015-04-22	2021-07-30	Biogen Ma Inc.	Novi hibridni proteini ligandske pasti actriib za zdravljenje bolezni zaradi izgube mišične mase
WO2016205370A1 (fr)	2015-06-15	2016-12-22	Santa Maria Biotherapeutics, Inc.	Méthodes d'utilisation de protéines à base du récepteur iib de l'activine
CA2996996A1 (fr)	2015-08-31	2017-03-09	National Research Council Of Canada	Molecules de fusion d'ectodomaines du recepteur du tgf-b et leurs utilisations
EP3439741B1 (fr)	2016-04-06	2026-05-20	Acceleron Pharma Inc	Hétéromultimères actriib:alk7 pour la réduction thérapeutique du poids corporel
EP3481860A4 (fr)	2016-07-07	2020-01-22	Acceleron Pharma Inc.	Hétéromultimères de la superfamille tgf-bêta et leurs utilisations
US20180008672A1 (en)	2016-07-08	2018-01-11	Regeneron Pharmaceuticals, Inc.	Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018067879A1 (fr)	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Hétéromultimères alk4:actriib et leurs utilisations
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

2016
- 2016-04-06 BR BR112017021510A patent/BR112017021510A2/pt not_active IP Right Cessation
- 2016-04-06 MA MA041916A patent/MA41916A/fr unknown
- 2016-04-06 CN CN202210568634.1A patent/CN115073610A/zh active Pending
- 2016-04-06 ES ES20206064T patent/ES3057446T3/es active Active
- 2016-04-06 CA CA2981833A patent/CA2981833A1/fr active Pending
- 2016-04-06 EP EP16777229.2A patent/EP3280728B1/fr active Active
- 2016-04-06 HK HK18109788.7A patent/HK1250373A1/zh unknown
- 2016-04-06 CN CN202210222650.5A patent/CN114736307A/zh active Pending
- 2016-04-06 CN CN201680032890.1A patent/CN107847561B/zh not_active Expired - Fee Related
- 2016-04-06 JP JP2017552155A patent/JP7055636B2/ja not_active Expired - Fee Related
- 2016-04-06 ES ES16777229T patent/ES2863564T3/es active Active
- 2016-04-06 US US15/092,577 patent/US10227392B2/en active Active
- 2016-04-06 EP EP25162196.7A patent/EP4599888A3/fr active Pending
- 2016-04-06 CN CN201680033093.5A patent/CN107709358A/zh active Pending
- 2016-04-06 JP JP2017552491A patent/JP7037363B2/ja not_active Expired - Fee Related
- 2016-04-06 AU AU2016244750A patent/AU2016244750B2/en not_active Ceased
- 2016-04-06 KR KR1020177031991A patent/KR20180002661A/ko not_active Ceased
- 2016-04-06 CA CA2981737A patent/CA2981737A1/fr active Pending
- 2016-04-06 EA EA201792222A patent/EA037293B1/ru not_active IP Right Cessation
- 2016-04-06 EP EP21161146.2A patent/EP3889171B1/fr active Active
- 2016-04-06 MX MX2017012846A patent/MX391964B/es unknown
- 2016-04-06 MA MA41920A patent/MA41920B1/fr unknown
- 2016-04-06 HK HK18112314.4A patent/HK1252957A1/zh unknown
- 2016-04-06 WO PCT/US2016/026277 patent/WO2016164503A1/fr not_active Ceased
- 2016-04-06 AU AU2016246708A patent/AU2016246708B2/en not_active Expired - Fee Related
- 2016-04-06 DK DK16777229.2T patent/DK3280728T3/da active
- 2016-04-06 KR KR1020177031989A patent/KR20180002659A/ko not_active Ceased
- 2016-04-06 WO PCT/US2016/000033 patent/WO2016164089A2/fr not_active Ceased
- 2016-04-06 US US15/092,609 patent/US10227393B2/en active Active
- 2016-04-06 MA MA054328A patent/MA54328A/fr unknown
- 2016-04-06 EP EP20206064.6A patent/EP3828199B1/fr active Active
- 2016-04-06 EP EP16777003.1A patent/EP3280435B1/fr active Active
- 2016-04-06 MA MA053400A patent/MA53400A/fr unknown
- 2016-04-06 EA EA202190016A patent/EA202190016A1/ru unknown
2019
- 2019-01-18 US US16/251,325 patent/US10906958B2/en active Active
- 2019-01-18 US US16/251,935 patent/US11028145B2/en active Active
2020
- 2020-11-18 US US16/951,192 patent/US20220396607A1/en not_active Abandoned
- 2020-12-04 AU AU2020281136A patent/AU2020281136A1/en not_active Abandoned
2021
- 2021-01-27 AU AU2021200492A patent/AU2021200492A1/en not_active Abandoned
- 2021-04-15 JP JP2021069060A patent/JP7246618B2/ja active Active
- 2021-04-30 US US17/245,123 patent/US11827689B2/en active Active
2023
- 2023-08-21 US US18/236,082 patent/US20240158468A1/en active Pending

Also Published As

Publication number	Publication date
EP3280435A4 (fr)	2018-12-19
AU2020281136A1 (en)	2021-01-07
EP3889171B1 (fr)	2025-03-12
EP4599888A3 (fr)	2025-10-29
EA201792222A1 (ru)	2018-04-30
EP3280435B1 (fr)	2021-06-02
WO2016164503A1 (fr)	2016-10-13
MX391964B (es)	2025-03-21
US11028145B2 (en)	2021-06-08
CN115073610A (zh)	2022-09-20
JP2018513147A (ja)	2018-05-24
CN107847561B (zh)	2022-03-29
EP3828199A1 (fr)	2021-06-02
MA41920B1 (fr)	2021-05-31
BR112017021510A2 (pt)	2018-07-03
JP7055636B2 (ja)	2022-04-18
US20190375820A1 (en)	2019-12-12
EP3280435A2 (fr)	2018-02-14
MA41920A (fr)	2018-02-14
CN107709358A (zh)	2018-02-16
CA2981833A1 (fr)	2016-10-13
EP3828199B1 (fr)	2025-10-15
US10227392B2 (en)	2019-03-12
EP3280728A1 (fr)	2018-02-14
US20220119491A1 (en)	2022-04-21
ES2863564T3 (es)	2021-10-11
WO2016164089A2 (fr)	2016-10-13
WO2016164089A3 (fr)	2016-12-08
US10906958B2 (en)	2021-02-02
US20160298093A1 (en)	2016-10-13
US20160297867A1 (en)	2016-10-13
US10227393B2 (en)	2019-03-12
EA037293B1 (ru)	2021-03-05
AU2016246708B2 (en)	2020-12-24
AU2016244750B2 (en)	2021-02-18
JP2018517399A (ja)	2018-07-05
CA2981737A1 (fr)	2016-10-13
AU2016246708A1 (en)	2017-10-26
ES3057446T3 (en)	2026-03-02
AU2021200492A1 (en)	2021-02-25
JP7246618B2 (ja)	2023-03-28
EP4599888A2 (fr)	2025-08-13
KR20180002661A (ko)	2018-01-08
EP3889171A1 (fr)	2021-10-06
EP3280728A4 (fr)	2018-09-12
US20220396607A1 (en)	2022-12-15
HK1248735A1 (zh)	2018-10-19
JP7037363B2 (ja)	2022-03-16
EP3280728B1 (fr)	2020-12-16
MA54328A (fr)	2021-10-06
DK3280728T3 (da)	2021-03-01
US20190225669A1 (en)	2019-07-25
US20240158468A1 (en)	2024-05-16
KR20180002659A (ko)	2018-01-08
CN107847561A (zh)	2018-03-27
EA202190016A1 (ru)	2021-08-31
CN114736307A (zh)	2022-07-12
US11827689B2 (en)	2023-11-28
MX2017012846A (es)	2018-11-09
AU2016244750A1 (en)	2017-10-26
HK1252957A1 (zh)	2019-06-06
JP2021104057A (ja)	2021-07-26
MA41916A (fr)	2021-04-14
HK1250373A1 (zh)	2018-12-14
HK1248733A1 (zh)	2018-10-19

Publication	Publication Date	Title
FR26C1010I1 (fr)	2026-04-17	Anticorps thérapeutiques et leurs utilisations
MA46472A (fr)	2019-08-14	Hétéromultimères alk4:actriib et leurs utilisations
MA55044A (fr)	2021-12-29	Hétéromultimères alk4:actriib et leurs utilisations
MA50618A (fr)	2020-08-12	Polyrhérapies et leurs utilisations
EP3600273A4 (fr)	2021-01-20	Inhibiteurs de cd73 et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
EP3328895A4 (fr)	2019-08-21	Anticorps anti-pd-l1 et leurs utilisations
EP3471727A4 (fr)	2019-10-09	Inhibiteurs de cxcr4 et leurs utilisations
MA46471A (fr)	2021-05-19	Protéines actriib à variant et leurs utilisations
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
EP3472129A4 (fr)	2019-12-04	Inhibiteurs de cxcr4 et leurs utilisations
MA53184A (fr)	2021-05-26	Anticorps anti-ox40 et leurs utilisations
EP3377102C0 (fr)	2023-08-09	Anticorps anti-pd-1 et leurs utilisations thérapeutiques
EP3283516A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
DK3280728T3 (da)	2021-03-01	Alk7:actriib-heteromultimerer og anvendelser deraf
EP3356416A4 (fr)	2019-04-10	Anticorps anti-pd-1 et ses utilisations
EP3389658A4 (fr)	2019-07-10	Inhibiteurs de glycosidase et leurs utilisations
EP3334706A4 (fr)	2019-03-13	Pillararènes et utilisations de ceux-ci
EP3349802A4 (fr)	2019-03-20	Dendrimères lipocationiques et leurs utilisations
EP3383904A4 (fr)	2019-12-04	Anticorps ctla-4 et leurs utilisations
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
EP3624797A4 (fr)	2021-07-21	Inhibiteurs de kinase et leurs utilisations
EP3370528A4 (fr)	2019-05-01	Compositions probiotiques et leurs utilisations
EP3478516A4 (fr)	2020-03-04	Structures multicouches et leurs utilisations
MA43567A (fr)	2018-11-14	Anticorps pacap et leurs utilisations